Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients

This study has been completed.
Sponsor:
Collaborators:
National Medical University, Ukraine
Immunitor USA Inc.
Information provided by (Responsible Party):
Lisichansk Regional Tuberculosis Dispensary
ClinicalTrials.gov Identifier:
NCT01222338
First received: June 30, 2010
Last updated: August 2, 2012
Last verified: August 2012
  Purpose

Treatment of multidrug-resistant TB (MDR-TB) is 100 times more expensive than treatment of drug-susceptible TB, requiring intensive clinical management for prolonged time (18-24 months) and more toxic treatment course. In prior open label study the investigators have shown that adding V-5 Immunitor (V5), can reduce treatment duration to one month and enhance by 4-5 fold the efficacy of TB drugs. Furthermore, V5 has been shown to reverse or reduce liver damage caused by chemotherapy. The cost of V5 will be very modest. The investigators propose to conduct placebo-controlled clinical trial in patients with treatment refractory TB so that the clinical benefit of V5 is confirmed.


Condition Intervention Phase
Tuberculosis
Biological: V-5 immunitor
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients

Resource links provided by NLM:


Further study details as provided by Lisichansk Regional Tuberculosis Dispensary:

Primary Outcome Measures:
  • primary endpoint: sputum smear conversion [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Sputum smear conversion at monthly intervals timepoint Rates of pulmonary healing by chest X-ray at the end of study


Secondary Outcome Measures:
  • liver function [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    To determine the safety of V5+ATT versus ATT+placebo in TB-infected subjects, Standard parameters, e.g., ALT and bilirubin, liver size will be measured.

  • quality of life [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Measure changes in quality of life by TB score questionnaire

  • hematology parameters [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Measure CBC by standard routine methods

  • weight gain [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Measure changes in body weight


Enrollment: 123
Study Start Date: January 2010
Study Completion Date: January 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Immunomodulator intervention
Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
Biological: V-5 immunitor
once per day dosing for 2 months
Other Name: V5, V-5 immunitor
Placebo Comparator: placebo
Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
Biological: V-5 immunitor
once per day dosing for 2 months
Other Name: V5, V-5 immunitor

Detailed Description:

The first-diagnosed Mycobacterium tuberculosis infection (TB) is curable with the first line of anti-tuberculosis drugs (ATT) in over 90% of cases within 6 months. The treatment of TB, refractory to conventional ATT, requires the deployment of second line TB drugs. This represents a significant challenge, particularly in resource-poor countries.

The incidence of TB in Ukraine prior to 1992 was about 40 cases per 100,000 people. Ten years later, TB cases increased to over 80/100,000, with mortality doubled from 10.2/100,000 to 21.6/100,000. Drug-resistant TB is now common in Ukraine. Isoniazid and rifampicin resistance, which defines the MDR-TB, has been found in 44% and 32.9% of TB isolates. The first Ukrainian case of HIV was reported in 1987. Today, Ukraine has the highest HIV rate in the Eastern Europe, with increasing proportion of dual infection. For example, in 2002 the prevalence of TB and HIV co-infection was 6.3%, but in 2006 at least 15.5 % of TB patients had HIV co-infection.

It is clear that alternative and improved treatment options are needed. If such an intervention is found, the impact on the healthcare and clinical management of treatment-refractory TB and TB-HIV patients will be tremendous. The significant efforts are directed at finding new drugs and vaccines against TB. Immune-based interventions are actively sought as an adjunct therapy to conventional ATT. In earlier study the investigators have accidentally observed that when patients with chronic hepatitis C and HIV-TB were given V5 together with TB drugs it resulted in negative sputum conversion in 95% of patients within one month. This startling finding had prompted this study. The aim of the present study is to compare the clinical benefit of TB therapy in combination with V5 versus combination of placebo with ATT in a representative population of patients who are poorly manageable due to relapsing TB, MDR-TB, or TB-HIV co-infection.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who are at least 18 years old and are willing and capable of providing written-informed consent.
  • Both men and non-pregnant women will be included.
  • One group of 30 patients will have HIV.
  • Another group of 30 patients will have drug-resistant TB (MDR or XDR).
  • Remaining 60 patients will have drug-sensitive TB of which 30 will be assigned to placebo.
  • TB infection documented prior to Study Entry by either the presence of TB rapid test or sputum smear positive for acid-fast bacilli (AFB).
  • At least two independent tests are sought to confirm TB diagnosis.
  • Agreement to participate in the study and to give a sample of blood for HIV testing.

Exclusion Criteria:

  • Subjects who have already taken V5 in prior trial and those without baseline data.
  • Those who met inclusion criteria can be retrospectively enrolled.
  • Those who are re-treated and relapsed will be eligible as long as they are on the same drug regimen as the rest of patients.
  • Pregnant or breast-feeding women are excluded.
  • Subjects who have taken anti-retroviral drugs or immunomodulatory therapies within 2 months prior to Entry:

    • systemic corticosteroids
    • immune globulin (IV gamma globulin, IVIG)
    • interferons,
    • interleukins
    • pentoxifylline (Trental)
    • thalidomide
    • filgrastim (G-CSF)
    • sargramostim (GM-CSF)
    • dinitrochlorobenzene (DNCB)
    • thymosin alpha 1 (thymosin alpha)
    • thymopentin
    • inosiplex (Isoprinosine)
    • polyribonucleoside (Ampligen)
    • ditiocarb sodium (Imuthiol)
    • any locally available immune modulators
    • and any other therapeutic or preventive vaccine.
  • Subjects requiring concurrent participation in another experimental research treatment study, or who received an experimental agent within four weeks prior to Study Entry.
  • Medical conditions that in the opinion of the local investigator, may obscure the proper observation of the safety or activity of the study treatment; including any acute medical condition of unknown etiology or recent surgery prior to Entry.
  • Medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator, would interfere with adherence to the requirements of this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01222338

Locations
Ukraine
Lisichansk TB Dispensary
Lisichansk, Luhansk, Ukraine, 20001
Sponsors and Collaborators
Lisichansk Regional Tuberculosis Dispensary
National Medical University, Ukraine
Immunitor USA Inc.
Investigators
Principal Investigator: Dmytro Butov, MD Kharkiv National Medical University
  More Information

Additional Information:
No publications provided by Lisichansk Regional Tuberculosis Dispensary

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Lisichansk Regional Tuberculosis Dispensary
ClinicalTrials.gov Identifier: NCT01222338     History of Changes
Other Study ID Numbers: imm01
Study First Received: June 30, 2010
Last Updated: August 2, 2012
Health Authority: Ukraine: Ministry of Health

Keywords provided by Lisichansk Regional Tuberculosis Dispensary:
Mycobacterium
MDR-TB
XDR-TB
HIV
HCV

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 14, 2014